ArticleAntimicrobial agents and chemotherapy2026
Repeated emergence and fitness heterogeneity of KPC-33 in ST11
Fangling Du, Xinyue Dai, Yuxuan Liu, Chuwen Zhao, Hanxu Hong, Yun Cao, Dandan Wei, Yang Liu
Abstract read
In one paragraphArticle in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Fangling Du *Department of Clinical Laboratory, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, People's Republic of China.ORCID 0009-0001-4333-2051 Xinyue Dai *Department of Clinical Laboratory, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, People's Republic of China.ORCID 0009-0005-7156-7551 Yuxuan LiuDepartment of Clinical Laboratory, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, People's Republic of China.
Chuwen ZhaoDepartment of Clinical Laboratory, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, People's Republic of China.
Hanxu HongDepartment of Clinical Laboratory, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, People's Republic of China.ORCID 0009-0005-0937-429X Yun CaoDepartment of Clinical Laboratory, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, People's Republic of China.
Dandan WeiDepartment of Clinical Laboratory, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, People's Republic of China.
Yang LiuDepartment of Clinical Laboratory, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, People's Republic of China.ORCID 0009-0009-1869-3558 Funding
National Natural Science Foundation of China 32370195, 82102411, 82260403Natural Science Foundation of Jiangxi Province 20242BAB20428Youth Project of Jiangxi Provincial Health Commission 202510273
6 · The paper itselfAbstract
Ceftazidime-avibactam (CZA) is an important therapeutic option for infections caused by
Indexed as
Anti-Bacterial AgentsAzabicyclo CompoundsBacterial Proteinsbeta-LactamasesCeftazidimeKlebsiella pneumoniaeDrug CombinationsHumansKlebsiella InfectionsMicrobial Sensitivity TestsThird Generation CephalosporinsWhole Genome SequencingAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsBacterial Proteinsbeta-LactamasescarbapenemaseCeftazidimeDrug CombinationsThird Generation Cephalosporinsceftazidime–avibactamfitness costKlebsiella pneumoniaeKPC-33resistance evolution
Identifiers
PMID42720552
PMCPMC13689381
What OpenQuestion holds
Textmetadata
Read underepoch 390